1 active not recruiting, 1 completed. 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Active not recruiting 1, Completed 1 |
Follow Oligodendroglioma: new trials by email Literature Review of Oligodendroglioma trials Research Report on Oligodendroglioma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparing Telehealth and In-person Assessments in Glioma Patients Receiving Oral Chemotherapy Assessment, Questionnaire Administration, Telemedicine Visit - Astrocytoma, IDH-Mutant, Glioblastoma | Phase 4 | Completed | Mayo Clinic | 30 | 2024-10-07 | 2026-04-29 |
| Pediatric Long-Term Follow-up and Rollover Study dabrafenib, trametinib - Diffuse Astrocytoma, Anaplastic Astrocytoma | Phase 4 | Active not recruiting | Novartis Pharmaceuticals | 163 | 2019-11-04 | 2026-08-27 |
Astrocytoma (2) · Glioblastoma (2) · Glioma (2) · Ganglioglioma (1) · Ganglioneuroma (1) · Histiocytosis, Langerhans-Cell (1) · Neuroblastoma (1) · Neurocytoma (1) · Neurofibroma, Plexiform (1) · Neurofibromatosis 1 (1)
Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms, Germ Cell and Embryonal (2) · Neoplasms, Glandular and Epithelial (2) · Neoplasms, Nerve Tissue (2) · Neoplasms, Neuroepithelial (2) · Neuroectodermal Tumors (2) · Brain Diseases (1) · Brain Neoplasms (1) · Central Nervous System Diseases (1) · Central Nervous System Neoplasms (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Genetic Diseases, Inborn (1) · Hemic and Lymphatic Diseases (1) · Heredodegenerative Disorders, Nervous System (1)
Observational Studies as Topic (1) · Outcome Assessment, Health Care (1) · Restraint, Physical (1) · Temozolomide (1) · dabrafenib (1) · trametinib (1)
Mayo Clinic (1) · Novartis Pharmaceuticals (1)
United States (2) · Argentina (1) · Australia (1) · Belgium (1) · Brazil (1) · Canada (1) · Czechia (1) · Denmark (1) · Finland (1) · France (1) · Germany (1) · Israel (1) · Italy (1) · Japan (1) · Netherlands (1)
Tufia C. Haddad, MD (1) · Ugur T. Sener, MD (1)
2023 (1)